908 Devices (NASDAQ:MASS) Director Sells $85,261.26 in Stock

908 Devices Inc. (NASDAQ:MASS) Director Christopher Brown sold 9,442 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $9.03, for a total transaction of $85,261.26. Following the completion of the transaction, the director directly owned 813,917 shares of the company’s stock, valued at approximately $7,349,670.51. The trade was a 1.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

908 Devices Trading Up 0.1%

Shares of 908 Devices stock traded up $0.01 during trading on Wednesday, hitting $10.02. The stock had a trading volume of 858,415 shares, compared to its average volume of 312,253. 908 Devices Inc. has a 12 month low of $5.03 and a 12 month high of $10.52. The firm has a market cap of $378.90 million, a price-to-earnings ratio of -10.02 and a beta of 0.66. The business’s 50-day moving average is $8.23 and its 200 day moving average is $7.34.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. The company had revenue of $16.07 million during the quarter, compared to analyst estimates of $15.37 million. 908 Devices had a negative return on equity of 14.03% and a negative net margin of 62.40%. As a group, equities analysts expect that 908 Devices Inc. will post -0.4 EPS for the current year.

Institutional Investors Weigh In On 908 Devices

Several hedge funds have recently added to or reduced their stakes in MASS. Allworth Financial LP bought a new position in shares of 908 Devices during the 2nd quarter valued at about $29,000. Raymond James Financial Inc. bought a new stake in 908 Devices in the 2nd quarter worth approximately $48,000. Intelligence Driven Advisers LLC bought a new stake in 908 Devices in the 1st quarter worth approximately $61,000. Daiwa Securities Group Inc. purchased a new stake in 908 Devices in the second quarter worth approximately $61,000. Finally, PCM Encore LLC purchased a new stake in 908 Devices in the fourth quarter worth approximately $62,000. Institutional investors own 88.06% of the company’s stock.

Key Headlines Impacting 908 Devices

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 results exceeded expectations. 908 Devices reported revenue of $16.07 million, up 23% year over year and above the $15.37 million analyst estimate. Its adjusted loss of $0.11 per share was narrower than the expected $0.14 loss and improved from a $0.18 loss a year earlier. 908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $68 million to $70 million, lifting the low end of its prior outlook and broadly bracketing the $68.6 million consensus estimate. The outlook excludes potential AVCAD revenue, leaving possible upside if that business contributes. 908 Devices signals 68M-70M 2026 revenue outlook
• Positive Sentiment: Demand and recurring revenue remain key growth drivers. Law-enforcement, defense, and other mission-critical customers are supporting demand for chemical detection devices. Recurring revenue from NIRLab and upgrades such as VipIR may provide additional stability, while management said the adjusted EBITDA loss narrowed by more than half year over year. 908 Devices: Mission Critical Devices Drive Growth
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
• Neutral Sentiment: Reported short interest was listed at zero shares, offering no meaningful evidence of short-selling pressure or potential short-covering demand.
• Negative Sentiment: The company remains unprofitable, with a negative net margin and return on equity. Although losses improved, continued negative EPS and the stock’s sharp recent appreciation could increase valuation sensitivity if growth or guidance disappoints.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MASS. Roth Capital upped their price objective on shares of 908 Devices from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of 908 Devices in a research report on Friday. Wall Street Zen cut shares of 908 Devices from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, Stifel Nicolaus increased their price target on shares of 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.50.

908 Devices Company Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.